[200] investigated the therapeutic potential of MSA‐1, a new STING agonist, in multiple murine tumor models, including immunogenic (LL‐2, B16F10, TC‐1) and nonimmunogenic (4T1) cancers. Here, STING1 is linked to neoplasm.